Regulatory Scrutiny

FDA Requests Additional Safety Data for Lilly's Foundayo Obesity Drug

The FDA has requested Eli Lilly conduct additional long-term safety studies for its newly approved oral obesity drug Foundayo, specifically flagging risks like heart attack, stroke, and liver injury.